Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of The Precision Peptide Company Inc. Street Ideas Just Put (CSE: BPC / OTCQB: PNGAF) On The Watchlist For Tomorrow Morning—Wednesday, October 21, 2026 Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. See Why We’re Highlighting (CSE: BPC / OTCQB: PNGAF) For Tomorrow Morning… October 20, 2026 Dear Reader, The numbers behind the GLP-1 category have shifted faster than most analysts expected… Gallup now reports that roughly 11% of U.S. adults are using a GLP-1 medication — nearly four times the rate measured just two years ago. That kind of acceleration doesn’t happen quietly. It rewrites the competitive dynamics for every company operating in the peptide therapeutics space — and it exposes the single biggest constraint the category still hasn’t solved… The compounds work. The consumer demand is there. What hasn’t changed is the delivery method. The vast majority of this market still runs through syringes, cold-chain logistics, and clinical supervision — a format that actively limits how far adoption can spread. An estimated 20 to 30% of young adults report needle fear, and a meaningful share of GLP-1 patients drop injectable therapy within the first twelve months. That’s not a minor friction point — it’s a structural ceiling on a category projected to nearly triple in value over the next decade. Which is what makes the development pace at The Precision Peptide Company Inc. (CSE: BPC / OTCQB: PNGAF) worth examining closely right now… The company has been building a proprietary transdermal patch platform designed to remove the needle from the equation entirely — and the progress in recent weeks has been notable. We’ll have full coverage on (CSE: BPC / OTCQB: PNGAF) tomorrow morning — Wednesday, October 21, 2026. 
The company is building its answer around a proprietary transdermal delivery matrix — a platform that turns injectable peptides into room-temperature, pre-measured patches requiring no syringes, no mixing, no refrigeration, and no cold-chain logistics. It already has one patch on sale, one in production, one in formal U.S. testing, and a fourth that just entered development… That’s four needle-free peptide patches moving through a single U.S.-based infrastructure in the space of a few months. And the market they’re aimed at is enormous. The Delivery Gap Nobody Closed Here's what gets overlooked about the peptide boom… The science has been validated for years. The consumer demand has been building for years. What hasn't existed is a convenient, compliant, consumer-grade format that removes the syringe from the equation. Research cited in the company's October 13 press release notes that needle fear affects an estimated 20 to 30% of young adults. A significant proportion of patients discontinue injectable GLP-1 therapy within the first year. That matters because the global GLP-1 receptor agonist market was valued at approximately US$66B in 2025 and is projected to reach US$185.3B by 2033, per Grand View Research and Fortune Business Insights. Existing tirzepatide products — Mounjaro and Zepbound, both delivered by injection — generated roughly US$36.5B in 2025 alone, according to Eli Lilly's fourth-quarter filings. That kind of adoption curve, running headlong into a delivery format that still demands needles and refrigeration, creates a clear gap… And it's worth noting that injectable delivery still accounts for 69.1% of the GLP-1 market — meaning the vast majority of this category is still locked behind the very barrier that drives patient dropout. The Precision Peptide Company Inc. (CSE: BPC / OTCQB: PNGAF) is building directly into that gap with its transdermal patch line — and the development pace (PNGAF) has maintained in recent weeks tells its own story. Four Patches, One Platform 
The development velocity here is what makes this name worth watching. The BPC-157 Recovery Patch — the company's first transdermal product — is already on sale, with independent third-party testing confirming 95.5% chromatographic purity and a 2.02 mg content per patch. That initial production run of 20,000 units was received in July 2026. BPC-157 itself is a synthetic peptide studied for its tissue-repair and anti-inflammatory properties — and the company's patch format eliminates the injection step that has historically limited its accessibility to a narrow subset of wellness-focused consumers. Next in line: 20,000 units of the Thymosin Alpha-1 (TA-1) Immunity Patch have been ordered and are expected for delivery in January 2027. TA-1 is a naturally occurring peptide studied for its immune-modulating properties, historically delivered by injection… The company believes it could be among the first to market with a needle-free TA-1 format. That's a meaningful distinction in a peptide space where nearly every product on the market still requires a syringe. If the company can deliver TA-1 through the same transdermal matrix that already works for BPC-157, it validates the platform's flexibility across peptide categories — not just one molecule, but the method itself. Then there's the tirzepatide GLP-1 patch, which entered formal U.S. testing in October 2026 — the third product to advance through the company's stage-gated transdermal pathway. The tirzepatide molecule sits at the heart of the current GLP-1 wave… It's the active ingredient behind Mounjaro and Zepbound — and bringing it into a patch format could open up the category to a population that has so far been sidelined by needle aversion, storage requirements, and the complexity of self-injection protocols. And just this week, The Precision Peptide Company Inc. (CSE: BPC / OTCQB: PNGAF) announced development of its GLP3 patch, the fourth needle-free product in its line and its second in the metabolic and we-ight-management category. Each product follows the same repeatable model: U.S. formulation, formal U.S. testing, commercial production order, and release. CEO Pratap Sandhu put it plainly in the GLP3 announcement: the company is not changing the method with each new peptide — it is repeating it. That's not a one-off… It's a pipeline running on a platform. Distribution That's Already Built What separates (PNGAF) from a pure-development story is the infrastructure already in place behind it. The company runs a direct-to-consumer platform at precisionpeptidecompany.com with physician-guided protocols across GLP-1, Sermorelin, and NAD+. Prescription products are dispensed through a nationwide telehealth platform and compounded 100% in the United States via a 503A partner pharmacy — with capacity for up to approximately 25,000 prescriptions per day. That capacity figure is worth pausing on. It suggests (PNGAF) isn't building a boutique operation — it's building infrastructure designed to handle scale from day one. On the wholesale side, the U.S. wholesale channel opened in late September 2026, accepting applications from gyms, fight academies, longevity clinics, med spas, physio and chiro practices, and specialty retailers nationwide. Every order ships from the company's own U.S. fulfillment operation — no third-party warehouse sits between (PNGAF) and its partners. And then there’s the exclusive strategic marketing agreement signed May 2026 with a major combat-sports platform, which gives The Precision Peptide Company Inc. (CSE: BPC / OTCQB: PNGAF) access to a network spanning over 5M social followers, 530K user profiles, and 800+ verified gyms across multiple countries. The revenue-share terms ramp from 50/50 in the first twelve months to 75/25 in favor of the company thereafter. That partnership already produced ringside sponsorship at the Championing Mental Health 3 boxing event, broadcast on UFC Fight Pass to audiences in more than 200 countries and territories. DTC, wholesale, telehealth, and an audience partnership — all running simultaneously. That multi-channel approach matters because it means (PNGAF) isn't dependent on a single revenue pathway… Each channel reinforces the others — wholesale partners introduce the brand to new audiences, DTC captures higher margins, telehealth extends reach into prescription categories, and the combat-sports partnership provides a built-in marketing engine at scale. The broader peptide therapeutics market, for context, was estimated at US$56.06B in 2026 and is projected to reach US$87.21B by 2035, per Precedence Research… And (PNGAF) is operating at the intersection of that science and consumer-grade delivery. 
Meanwhile, the July 2026 FDA Pharmacy Compounding Advisory Committee convened to review seven peptide-related bulk dr-ug substances — a sign that U.S. regulators are paying close attention to the peptide space and rewarding companies built compliant from day one. That regulatory backdrop could matter more than most people realize… A tightening compliance environment tends to favor the companies that were built to meet those standards before they became mandatory — and (PNGAF) has made U.S.-based manufacturing, LegitScript certification, and FDA-registered facilities central to its model from the start. 7 Reasons Why We’ll Be Watching The Precision Peptide Company Inc. (CSE: BPC / OTCQB: PNGAF) Tomorrow Morning —Wednesday, October 21, 2026 1. Massive GLP-1 Addressable Market: The global GLP-1 market was valued at US$66B in 2025 and is projected to reach US$185.3B by 2033, with injectable delivery still accounting for 69.1% of the market — suggesting significant room for needle-free alternatives. 2. Four-Product Transdermal Pipeline: The needle-free patch line now includes BPC-157 (on sale), TA-1 (in production), tirzepatide GLP-1 (in U.S. testing), and GLP3 (entering development) — four products moving through one repeatable U.S.-based development system. 3. Repeatable Development Model: Three products have now advanced through the company's transdermal pathway — BPC-157 through to commercial sale, TA-1 through to a 20,000-unit production order, and tirzepatide into formal testing — demonstrating a working, scalable process. 4. U.S.-Built Supply Chain: All products are manufactured in an approved U.S. facility, tested domestically, and distributed from the company's own U.S. fulfillment operation — per the company's press releases and its LegitScript certification. 5. Combat-Sports Audience Access: The exclusive strategic marketing agreement with a major combat-sports platform opens an audience of over 5M social followers and 530K user profiles, with a revenue-share structure ramping to 75/25 in the company’s favor from year two. 6. Telehealth and Pharmacy Infrastructure: A nationwide prescription pathway is already operational, with licensed U.S. physicians, 503A pharmacy compounding, and capacity for up to approximately 25,000 prescriptions per day — infrastructure that could scale with the GLP-1 adoption curve. 7. Live Wholesale Distribution Channel: The U.S. wholesale channel opened September 2026, putting the company's U.S.-made, non-prescription range in front of gyms, clinics, med spas, and retailers nationwide — a second revenue engine alongside DTC. See Why We’re Highlighting (CSE: BPC / OTCQB: PNGAF) For Tomorrow Morning… 
The peptide space is moving fast… The demand is real, the adoption numbers are accelerating, and the delivery bottleneck — needles, cold chains, clinic visits — remains the single biggest friction point between where the market is and where it wants to go. And The Precision Peptide Company Inc. (CSE: BPC / OTCQB: PNGAF) is building the infrastructure to meet that demand with something the category has needed for a long time — a needle-free format that works for the mainstream consumer. The Precision Peptide Company Inc. (CSE: BPC / OTCQB: PNGAF) will be the first name on our screen tomorrow morning. Don’t shut your eyes tonight without looking at this one. Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter Street-Ideas.com (“Street-Ideas” or “SI” ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 10/20/2026 and ending on 10/21/2026 to publicly disseminate information about (PNGAF:US) (BPC:CA) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC seven thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Emerging Markets Consulting LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither 147 Media LLC, TD Media LLC and their member own shares of (PNGAF:US) (BPC:CA). Please see important disclosure information here: https://street-ideas.com/disclosure/pngaf-ADnd3/#details |
Tidak ada komentar:
Posting Komentar